SEPMAG, the manufacturer of biomagnetic separation systems for the in vitro diagnostics sector, will mark its established entry and plans for further penetration of the Chinese IVD market with a presentation delivered at the State sponsored Clinical Laboratory Provider & Blood Transfusion Equipment Expo - taking place on March 11th in the Xi¡¯an Greenland Pico International Convention & Exhibition Centre, Shanxi province, China.
The company’s technology will be jointly presented by Apis Biotechnology and Sepmag itself, at the conference organised by the Chinese Association for Clinical Laboratory Providers (CACLP), and attended by high level life science audiences from across China. The event is sponsored by the National Association of Health Industry and Enterprise Management and the Chinese Association for Clinical Laboratory Providers. Moreover, the expo is supported by the Chinese Technical Committee of Clinical Laboratory Testing, together with the In Vitro Diagnostics Standardization Administration of China.
This latest development follows-on from the recent patent SEPMAG was awarded from China’s State Intellectual Property Office (SIPO), and marks the Company’s intentions to further expand revenues in China - a market still in its infancy, but forecast by analysts to expand at double digit pace over the coming years. As previously reported, SEPMAG has already commenced shipping the SEPMAG Q250ml to CapitalBio, its first client in the region, for the production of its IVD kits.
SEPMAG CEO, Josep Maria Simó will hold a two hour seminar (complete with live demonstrations) on Apis Biotechnology’s stand, explaining how homogeneous separation techniques will help assist rapid growth amongst the Country’s newly established in vitro diagnostic companies.
“The Chinese government is keen to develop China’s own diagnostics technologies and advance the IVD market within the country. The Chinese market has tremendous growth potential and the company is on the cusp of an explosion of new developments in this field. Using our technologies they will be able to develop more consistent and reliable and safer results with reduced bead aggregation. This will undoubtedly help to facilitate the growth of China’s IVD industry and we look forward to advancing research for the betterment of healthcare in the region” Josep Maria Simó.